---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-041275"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:14:58.307914+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics presents NAVIGATE trial: belapectin reduces varices, biomarkers improve

## Summary
- Belapectin 2 mg/kg reduced new varices vs placebo across all ELF risk categories at 18 months; in highest risk (ELF>11.3): 22.7% vs 42.9%.
- Pro-C3 biomarker showed >50% reduction from baseline at 18 months with belapectin 2 mg/kg vs placebo (mean -6.4 vs -4.5 ng/mL).
- Higher proportion of belapectin 2 mg/kg patients achieved ≥20% reduction in YKL-40 (33.8% vs 23.1%); fewer had ≥20% PRO-C4 increase (3% vs 13%).
- At 36 months, cumulative new varices incidence 12.4% (belapectin 2 mg/kg) vs 23.4% (placebo), sustained benefit.
- Safety profile encouraging; adverse events and serious adverse events comparable to placebo, no drug-related SAEs.

## SEC filing metadata
- accession: 0001140361-25-041275
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125041275/0001140361-25-041275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125041275/ny20058530x1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-041275
- JSON: https://secwatch.observer/filing/0001140361-25-041275.json
- Plain text: https://secwatch.observer/filing/0001140361-25-041275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.